475 related articles for article (PubMed ID: 31801360)
1. A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.
Chen S; Zhang Y; Lighthouse JK; Mickelsen DM; Wu J; Yao P; Small EM; Yan C
Circulation; 2020 Jan; 141(3):217-233. PubMed ID: 31801360
[TBL] [Abstract][Full Text] [Related]
2. Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
Wu MP; Zhang YS; Xu X; Zhou Q; Li JD; Yan C
Cardiovasc Drugs Ther; 2017 Apr; 31(2):157-166. PubMed ID: 28321644
[TBL] [Abstract][Full Text] [Related]
3. PDE10A Inactivation Prevents Doxorubicin-Induced Cardiotoxicity and Tumor Growth.
Chen S; Chen J; Du W; Mickelsen DM; Shi H; Yu H; Kumar S; Yan C
Circ Res; 2023 Jul; 133(2):138-157. PubMed ID: 37232184
[TBL] [Abstract][Full Text] [Related]
4. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.
Miller CL; Oikawa M; Cai Y; Wojtovich AP; Nagel DJ; Xu X; Xu H; Florio V; Rybalkin SD; Beavo JA; Chen YF; Li JD; Blaxall BC; Abe J; Yan C
Circ Res; 2009 Nov; 105(10):956-64. PubMed ID: 19797176
[TBL] [Abstract][Full Text] [Related]
5. Abstract MP265: The Role Of Phosphodiesterase 10a In Tumor Growth And Doxorubicin-induced Cardiotoxicity.
Chen S; Chen J; Shi H; Mickelsen D; Yan C
Circ Res; 2021 Sep; 129(Suppl_1):AMP265. PubMed ID: 34735298
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Karam S; Margaria JP; Bourcier A; Mika D; Varin A; Bedioune I; Lindner M; Bouadjel K; Dessillons M; Gaudin F; Lefebvre F; Mateo P; Lechène P; Gomez S; Domergue V; Robert P; Coquard C; Algalarrondo V; Samuel JL; Michel JB; Charpentier F; Ghigo A; Hirsch E; Fischmeister R; Leroy J; Vandecasteele G
Circulation; 2020 Jul; 142(2):161-174. PubMed ID: 32264695
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.
Padovan-Neto FE; Sammut S; Chakroborty S; Dec AM; Threlfell S; Campbell PW; Mudrakola V; Harms JF; Schmidt CJ; West AR
J Neurosci; 2015 Apr; 35(14):5781-91. PubMed ID: 25855188
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload.
Shinde AV; Su Y; Palanski BA; Fujikura K; Garcia MJ; Frangogiannis NG
J Mol Cell Cardiol; 2018 Apr; 117():36-48. PubMed ID: 29481819
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2.
Zoccarato A; Surdo NC; Aronsen JM; Fields LA; Mancuso L; Dodoni G; Stangherlin A; Livie C; Jiang H; Sin YY; Gesellchen F; Terrin A; Baillie GS; Nicklin SA; Graham D; Szabo-Fresnais N; Krall J; Vandeput F; Movsesian M; Furlan L; Corsetti V; Hamilton G; Lefkimmiatis K; Sjaastad I; Zaccolo M
Circ Res; 2015 Sep; 117(8):707-19. PubMed ID: 26243800
[TBL] [Abstract][Full Text] [Related]
10. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling.
Vandenwijngaert S; Pokreisz P; Hermans H; Gillijns H; Pellens M; Bax NA; Coppiello G; Oosterlinck W; Balogh A; Papp Z; Bouten CV; Bartunek J; D'hooge J; Luttun A; Verbeken E; Herregods MC; Herijgers P; Bloch KD; Janssens S
PLoS One; 2013; 8(3):e58841. PubMed ID: 23527037
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis.
Watson CJ; Horgan S; Neary R; Glezeva N; Tea I; Corrigan N; McDonald K; Ledwidge M; Baugh J
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):127-37. PubMed ID: 26130616
[TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.
Miller CL; Cai Y; Oikawa M; Thomas T; Dostmann WR; Zaccolo M; Fujiwara K; Yan C
Basic Res Cardiol; 2011 Nov; 106(6):1023-39. PubMed ID: 22012077
[TBL] [Abstract][Full Text] [Related]
13. Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy.
Perera RK; Sprenger JU; Steinbrecher JH; Hübscher D; Lehnart SE; Abesser M; Schuh K; El-Armouche A; Nikolaev VO
Circ Res; 2015 Apr; 116(8):1304-11. PubMed ID: 25688144
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 10A Is a Key Mediator of Lung Inflammation.
Hsu CG; Fazal F; Rahman A; Berk BC; Yan C
J Immunol; 2021 Jun; 206(12):3010-3020. PubMed ID: 34117108
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin Aβ-Specific Anchoring Confers Isoform-Specific Compartmentation and Function in Pathological Cardiac Myocyte Hypertrophy.
Li X; Li J; Martinez EC; Froese A; Passariello CL; Henshaw K; Rusconi F; Li Y; Yu Q; Thakur H; Nikolaev VO; Kapiloff MS
Circulation; 2020 Sep; 142(10):948-962. PubMed ID: 32611257
[TBL] [Abstract][Full Text] [Related]
16. Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1-Endothelin-1 Signal Pathway.
Liu J; Zhuang T; Pi J; Chen X; Zhang Q; Li Y; Wang H; Shen Y; Tomlinson B; Chan P; Yu Z; Cheng Y; Zheng X; Reilly M; Morrisey E; Zhang L; Liu Z; Zhang Y
Circulation; 2019 Aug; 140(8):665-680. PubMed ID: 31177814
[TBL] [Abstract][Full Text] [Related]
17. PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.
Knight WE; Chen S; Zhang Y; Oikawa M; Wu M; Zhou Q; Miller CL; Cai Y; Mickelsen DM; Moravec C; Small EM; Abe J; Yan C
Proc Natl Acad Sci U S A; 2016 Nov; 113(45):E7116-E7125. PubMed ID: 27791092
[TBL] [Abstract][Full Text] [Related]
18. Role of IgE-FcεR1 in Pathological Cardiac Remodeling and Dysfunction.
Zhao H; Yang H; Geng C; Chen Y; Pang J; Shu T; Zhao M; Tang Y; Li Z; Li B; Hou C; Song X; Wu A; Guo X; Chen S; Liu B; Yan C; Wang J
Circulation; 2021 Mar; 143(10):1014-1030. PubMed ID: 33305586
[TBL] [Abstract][Full Text] [Related]
19. Endothelial S1pr1 regulates pressure overload-induced cardiac remodelling through AKT-eNOS pathway.
Liu X; Wu J; Zhu C; Liu J; Chen X; Zhuang T; Kuang Y; Wang Y; Hu H; Yu P; Fan H; Zhang Y; Liu Z; Zhang L
J Cell Mol Med; 2020 Jan; 24(2):2013-2026. PubMed ID: 31854513
[TBL] [Abstract][Full Text] [Related]
20. FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Weeks KL; Tham YK; Yildiz SG; Alexander Y; Donner DG; Kiriazis H; Harmawan CA; Hsu A; Bernardo BC; Matsumoto A; DePinho RA; Abel ED; Woodcock EA; McMullen JR
Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1470-H1485. PubMed ID: 33577435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
